The list of drugs that have grabbed headlines for dizzyingly high prices are just the tip of the iceberg. Pharmaceutical companies’ habit of pushing the limits on drug prices is costing states like California billions and driving up the cost of healthcare.
Enough is enough. It’s time for solutions.
California Takes On Out-of-Control Prescription Drug Pricing
SB 17 BRINGS PHARMA’S PRICING TACTICS OUT OF THE SHADOWS
The pharmaceutical industry spent years stalling transparency legislation in the state legislature but, California families made progress in 2017 with the passage of SB 17. There’s more to be done, but this landmark law is paving the way for more sustainable, affordable prescription drug prices.
AB 824 SEEKS TO END PHARMA’S ANTI-COMPETITIVE PRICING TACTICS
Pay-for-delay agreements, also known as reverse payment settlements, occur when major brand-name pharmaceutical companies pay off generic manufacturers to delay entering their lower-priced generic versions of the drug into the market for a set period of time. Pay-for-delay agreements take money from patient pockets to unfairly increase drug company profits. AB 824 (Wood) is currently making its way through California’s Capitol. The law will give Attorney General Becerra greater tools to crack down on pay-for-delay schemes — bringing more generic drugs into the marketplace to ensure competition helps all Californians have access to more affordable health care. Read more about Pay-for-Delay.
Stay up to date on the fight against runaway prescription drug prices.
Increasing transparency to pressure prescription drug manufacturers to lower their prices works! One prescription drug company announced lower #COVID19 treatment prices following the Institute for Clinical and Economic Review (ICER) recommendations. More: https://t.co/S25eVBGUNe